Endeavor

Moffitt Completes 100th Percutaneous Hepatic Perfusion Since FDA approval

The procedure helps improve uveal melanoma outcomes, which accounts for 3% to 5% of all melanoma cases and has a high likelihood of metastasizing to the liver

HEPZATO Kit Continues To Improve Uveal Melanoma Outcomes After FDA Approval

The treatment was approved by the FDA in 2023 following a phase 3 trial at Moffitt

A First Chance at a First-Line Treatment

Percutaneous hepatic perfusion gave Patty Johnson an innovative option for treating metastatic uveal melanoma

Percutaneous Hepatic Perfusion Should Be Done First and Early for Metastatic Uveal Melanoma Patients

The pivotal phase III FOCUS study shows percutaneous hepatic perfusion (PHP) is best option

The Long Journey in Search of a Cure

With one TIL therapy approved by the FDA, doctors push to optimize the treatment. Michelle Shannon is living for the next breakthrough.

Eyeing New Therapies for Metastatic Uveal Melanoma

New $3.95 million multicenter grant will help researchers better understand the rare ocular cancer